<DOC>
	<DOCNO>NCT02990403</DOCNO>
	<brief_summary>In clinical cohort study , investigator go observe efficacy anti-coagulation immune therapy treatment recurrent pregnancy loss prospective randomize controlled trial .</brief_summary>
	<brief_title>The Novel Immunomodulatory Anticoagulant Therapies Recurrent Pregnancy Loss</brief_title>
	<detailed_description />
	<mesh_term>Abortion , Spontaneous</mesh_term>
	<mesh_term>Fetal Death</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Woman 2 miscarriage 12 ( th ) week gestation.The patient diagnose thrombophilia recurrent pregnancy loss . Signed consent form . 1. experience severe allergy , trauma history and/or operation history within 3 month . 2. history mental illness and/or family history mental illness limb disable . 3. take medicine within one month . 4. suffer major event mood swing . 5. internal surgical disease ( variety physical examination electrocardiogram/hepatic renal function/blood routine urine routine ) 6. chromosome aberration anyone couple . 7. patient drug contraindication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>